US FDA declines to approve Aldeyra's eye disease drug
The U.S. Food and Drug Administration has once again declined to approve Aldeyra Therapeutics treatment for dry eye disease, ...
Fierce Biotech11 小时
Aldeyra’s dry eye drug suffers second FDA rejection, but imminent data spur hope of fast ...
The FDA has set back Aldeyra Therapeutics’ ambitions to win approval for its dry eye disease, rejecting its second ...
Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug
Aldeyra Therapeutics shares fell 73% to $1.42 in the regular session after it reported a Food and Drug Administration complete response letter for reproxalap for treatment of dry eye disease. The ...
The American Journal of Managed Care10 小时
Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease
The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish ...
Alzheimer's Research UK2 天
Could diabetes and eye drugs be used to treat dementia?
He is studying methazolamide, a treatment currently used to manage glaucoma, to find out if it can also help treat ...
MPR7 小时
FDA Denies Approval of Reproxalap for Dry Eye Disease
The Company expects to have topline data from 2 trials assessing the effect of reproxalap on dry eye disease symptoms available in the second quarter of 2025.
Healio6 小时
FDA does not approve resubmitted new drug application for reproxalap
The FDA issued a complete response letter for the resubmission of the reproxalap new drug application for the treatment of ...
Fierce Biotech3 天
Opthea scraps wet AMD program after eye drug loses out to Lucentis in latest phase 3 fail
Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...